Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
137 studies found for:    gene expression analysis AND lymphoma
Show Display Options
Rank Status Study
1 Recruiting Clinical Factors and Gene Expression Analysis for Prognosis in Tissue Samples From Patients With AIDS-Related Primary Effusion Lymphoma
Condition: AIDS-Related Primary Effusion Lymphoma
Interventions: Genetic: Laboratory Biomarker Analysis;   Other: Medical Chart Review
2 Completed
Has Results
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: Rituximab;   Drug: Fludarabine phosphate;   Other: Leukemic or stroma cells
3 Completed Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells
Condition: Lymphoma
Intervention: Other: laboratory biomarker analysis
4 Unknown  Biomarkers in Tissue Samples From Patients With Hodgkin Lymphoma Enrolled on ECOG-2496 Clinical Trial
Condition: Lymphoma
Interventions: Genetic: gene expression analysis;   Other: laboratory biomarker analysis
5 Unknown  Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab
Condition: Lymphoma
Interventions: Genetic: gene expression analysis;   Other: laboratory biomarker analysis
6 Active, not recruiting S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Genetic: RNA analysis;   Genetic: gene expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
7 Completed Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
Conditions: Leukemia;   Lymphoma
Interventions: Genetic: gene expression analysis;   Other: laboratory biomarker analysis
8 Unknown  DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402
Condition: Lymphoma
Interventions: Biological: rituximab;   Genetic: DNA analysis;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
9 Terminated
Has Results
Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia
Conditions: Large Granular Lymphocytic Leukemia;   LGL Leukemia
Interventions: Drug: Cyclosporine;   Genetic: Gene expression analysis;   Genetic: Microarray analysis;   Other: Laboratory biomarker analysis
10 Unknown  Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab
Condition: Lymphoma
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
11 Recruiting Observational Controlled Clinical Trials, on Adult Patients With T-lymphoblastic Lymphoma Treated With Intensive Chemo/Radiotherapy or Intensive Chemotherapy Followed by Transplant. Evaluation of Clinical, Anatomy -Pathological Parameters
Condition: Lymphoblastic Lymphoma
Intervention: Other: Latest generation chemotherapies for T-LBL + transplant
12 Unknown  Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496
Condition: Lymphoma
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: polymorphism analysis;   Other: diagnostic laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Other: immunologic technique
13 Unknown  Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Genetic: DNA analysis;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: medical chart review
14 Terminated
Has Results
Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: bortezomib;   Drug: pegylated liposomal doxorubicin hydrochloride;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Genetic: proteomic profiling;   Other: flow cytometry;   Other: laboratory biomarker analysis
15 Unknown  GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Biological: sargramostim;   Genetic: gene expression analysis;   Genetic: gene rearrangement analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
16 Terminated
Has Results
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: clofarabine;   Genetic: DNA methylation analysis;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: polymerase chain reaction;   Other: high performance liquid chromatography;   Other: laboratory biomarker analysis
17 Unknown  GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Biological: sargramostim;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: gene expression analysis;   Genetic: gene rearrangement analysis;   Genetic: polymerase chain reaction;   Other: R-CHOP regimen;   Other: laboratory biomarker analysis
18 Unknown  Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Peripheral T-cell Lymphoma
Interventions: Drug: prednisone;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: vincristine sulfate;   Drug: pralatrexate;   Other: laboratory biomarker analysis;   Genetic: comparative genomic hybridization;   Genetic: gene expression analysis;   Genetic: nucleic acid sequencing;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Genetic: microarray analysis;   Genetic: RNA analysis
19 Terminated Oblimersen Sodium and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Biological: oblimersen sodium;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Procedure: biopsy;   Genetic: microarray analysis;   Other: immunohistochemistry staining method;   Genetic: gene expression analysis;   Genetic: cytogenetic analysis
20 Recruiting Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
Conditions: Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Drug: bortezomib;   Biological: rituximab;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: DNA analysis;   Other: pharmacological study;   Other: pharmacogenomic studies;   Other: Questionnaire Administration

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.